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SUMMARY 
Understanding the mechanism behind the cardioprotection induced by preconditioning might 
provide a new therapeutic tool against the life threatening ventricular arrhythmias that often lead 
to sudden cardiac death.  
Therefore in Study I, we aimed to investigate gene expression changes following ischemia and 
reperfusion in dogs subjected to rapid right ventricular cardiac pacing 24 hours previously by a 
genome-wide approach using cDNA microarray analysis. We also aimed to examine the 
transcription rate of 45 additional genes which have already been suggested to be involved in 
ischemic PC but little is known about their role in the cardiac pacing induced antiarrhythmic 
protection. Furthermore, in Study II, 29 genes were selected to explore the time course changes 
of gene expressions over 24 hours, which elapses between rapid cardiac pacing and the 
ischemia/reperfusion period. 
In Study I, we have identified 23 genes with altered expression; some of these, for example, 
MEF2A (involved in angiogenesis) or mAKAP (an anchoring protein), were firstly demonstrated 
to be significantly up-regulated in response to preconditioning.  
We have proved that rapid right ventricular pacing alters the expression of genes involved in the 
delayed protection. In Study I, 6 out of 45 genes exhibited significant down-regulation and 16 
showed up-regulations in response to ischemia and reperfusion, compared with the control dogs. 
Among these, genes encoding different proteins, such as NO producing enzymes, heat shock 
proteins, members of the survival signaling pathways or pro-apoptotic factors showed the most 
marked changes. In Study II, we have proved that pacing induces time-dependent alterations in 
the expression of the 29 genes examined. Immediately after the cessation of pacing, 8 genes 
showed significant up-regulation and 6 significant down-regulation. After these initial changes, 
some of these early up- or down-regulated genes either remained unchanged or showed a 
biphasic transcriptional pattern; i.e. after an initial change in their transcription these genes were 
normalized to the mRNA level of the unpaced hearts but their expression started to change again 
at later time points. There were also genes, such as those encode eNOS and iNOS, which 
exhibited significant up-regulation only 12h after the pacing stimulus. The resultant increase in 
eNOS protein content and activation certainly contributes to an increased NO production, to 
which we attribute an important role in late phase of the protection. We are aware that changes at 
gene expression level do not always reflect changes at protein level, nevertheless the present 
results provide evidence for gene expression changes following cardiac pacing, and when the 
antiarrhythmic protection is observed. 
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AEST S-(2-aminoethyl)-isothiourea 
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PI3K/ PI3 kinase  Phosphatidylinositol 3-kinase  
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Src  also known as tyrosine-protein kinase Src (short for sarcoma) 
SSC buffer  Saline-sodium citrate buffer 
TRIS-HCl  Tris(hydroxymethyl)aminomethane hydrochloride 
VBP  Ventricular premature beats 
VDAC  Voltage-dependent anion channel  
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1. INTRODUCTION 
One of the most important consequences of acute myocardial ischemia, is the occurrence of the 
life threatening ventricular arrhythmias, which are responsible in most instances for sudden 
cardiac death. This is one of the major causes of mortality in the developed countries. Due to 
several disadvantages of the current antiarrhythmic drug therapy, resulting from a proarrhythmic 
effect, significant efforts have been made to explore new therapeutic strategies against ventricular 
arrhythmias. For example preconditioning is one of the endogenous cardioprotective phenomena, 
which may offer a new tool to attenuate ventricular arrhythmias.  
 
1.1 The antiarhythmic effect of ischemic preconditioning and rapid cardiac pacing 
The cardioprotective phenomenon, termed ischemic or 'classic' preconditioning was first 
described by Murry et al. [1] in 1986. They have reported that multiple brief ischemic episodes 
protect the heart against the severe consequences of a more prolonged ischemic insult, such as 
ATP loss or myocardial cell death. Since then, it has been established that preconditioning not 
only reduces infarct size, but markedly attenuates the severity of the ischemia and reperfusion-
induced ventricular arrhythmias [2], and enhances the recovery of contractile function following 
ischemia and reperfusion [3].  
Apart from the ‘classical' ischemic preconditioning, there are other stimuli which are able to 
induce cardioprotection. For example, in dogs subjected to two, 2 min periods of cardiac pacing 
at a rate of 300 beats min
-1
, the number and the severity of arrhythmias, such as ventricular 
tachycardia and ventricular fibrillation, were markedly reduced compared with the unpaced 
controls [4].  
The antiarrhythmic effect of preconditioning appears in two phases. For example, Kaszala et al 
showed when pacing the hearts four times for 5 min, at a rate 240 beats min
-1 
there is an early 
protective phase, which occurs immediately after the stimulus, but it lasts for less than 1 h. The 
antiarrhythmic protection re-appears spontaneously approximately 20-24h later and, this phase is 
termed as delayed or ‘second window’ of protection [5]. Interestingly, if the pacing protocol is 
repeated at a time when the protection from the previous stimulus has already been lost (i.e. 48 h 
after the first pacing), the antiarrhythmic protection persists even for days [6].  
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1.2 Mechanism of the early protection induced by preconditioning  
Since first described in 1986, the phenomenon of preconditioning stimulated considerable interest 
to explore the underlying mechanism with the hope of finding a new therapeutic strategy against 
myocardial ischemic damage and its serious consequences. Despite the extensive research the 
precise mechanism by which preconditioning induces cardioprotection is still not fully 
understood.  
It is well accepted that endogenous substances generated and released from the myocardium in 
response to the preconditioning stimulus and play a role in the initiation and mediation of the 
protection, first published in [7]. These substances, such as adenosine, bradykinin, opioids, 
prostanoids, nitric oxide and ROS, bind to their receptors or other targets and activate different 
signal transduction pathways and end-effectors [8]. 
Studies identified numerous signaling pathways that might have important role in the early phase 
of the protection. For example, adenosine, bradykinin, prostanoids, opioids that are released by 
an ischemic stimulus bind to GPCR and activate PI3 kinase. This stimulates numerous 
downstream pathways, such as the PI3K-Akt-eNOS-NO-sGC-PKG, the PI3K-Akt-ERK, the 
PI3K-Akt-GSK3β or the PI3K-Akt-BAD/caspase9 mediated signaling processes reviewed by [8]. 
PKCε and ERK are also downstream parts of the PI3 cascade [8]. For example, we have 
demonstrated that the NO-sGC-PKG signaling pathway is important in the induction and 
mediation of the early protection. The experimental evidence comes from studies in which the 
inhibition of NO synthesis by L-NAME markedly attenuated the early antiarrhythmic protection 
[9]. Furthermore, the same result was observed if sGC was inhibited with methylene blue [10].  
These PC-induced survival pathways act on numerous end effectors. One of these, for example, is 
the mitochondria which plays a central role in the ischemia and reperfusion injury. During 
ischemia but mainly upon reperfusion, the ROS and Ca2+ overload lead to the forming and 
opening of the mPTP at the mitochondrial level, resulting in the depletion of ATP, irreversible 
oxidation of proteins, lipids, and DNA within the myocardium, and finally lead to robust 
mitochondrial swelling, cytochrome c release and later to cell death [11].  
The survival signaling, induced by PC, acts directly on the inhibition of mPTP or prevents the 
conditions which lead to the opening of mPTP. One of the end-effectors for this is the mitoKATP 
channels, which are involved in regulating mitochondrial matrix volume. Early studies showed 
that inhibitors of mitoKATP channels blocked [12] and the openers mimicked the protection 
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afforded by PC [13, 14]. The activated mitoKATP decreases mitochondrial membrane potential 
which reduces the Ca
2+
 uptake during ischemic damage [15]. This activation mechanism is 
conducted through the NO-mediated signaling and also by PKCε [16, 17]. The activation of 
mitoKATP also results in the release of small levels of ROS which is thought to play a trigger role 
in PC by further enhancing the activation of PKCε, thereby amplifying the survival signaling 
[18]. Another target of the survival signaling is to inhibit the formation of mPTP directly [19, 20]. 
The inhibition of GSK3β through the PI3K pathway reduces the formation of mPTP [21]. 
Furthermore, PKCε has also been shown to phosphorylate VDAC through which the mPTP 
formation is blocked [22].  
Apoptotic processes have also been implicated in ischemia and reperfusion injury. Apoptosis 
occurs via the activation of the caspase cascade which was also discovered as one of the targets 
of the survival pathways [23]. For example, Akt, activated after a PC stimulus, binds and inhibits 
the proapoptotic members of the Bcl-2 family, such as BAD and casp9 by phosphorylation 
through which the apoptotic processes are inhibited following the ischemia and reperfusion injury 
[24]. Another example is ERK, which is activated by PKCε in response to a PC stimulus and 
phosphorylates therefore inhibits the proapoptotic factor BAD [25].  
Apart from the changes in cell viability, the metabolic and electric communication between 
cardiomyocytes is also damaged during ischemia and reperfusion which is in close relation with 
the generation of arrhythmias [26]. There is evidence from in vitro experiments that PC preserves 
gap junction function by preventing the dephosphorylation of the main gap junction forming 
protein Cx43 resulting from myocardial ischemia [27]. In response to a PC stimulus, the activated 
survival kinases such as PKC isoforms (α and ε) as well as PKG phosphorylate Cx43 thereby 
contributing to the attenuation of the generation of arrhythmias after the coronary artery 
occlusion [27].  
 
1.3 Mechanism of the late protection induced by preconditioning 
There is abundant evidence that gene expression changes play an important role in the delayed 
phase of cardioprotection afforded by preconditioning, reviewed in [28]. The endogenous 
substances that are released by preconditioning serve as triggers for the development of the early 
phase trough activation of the survival signaling and acting on various end-effectors. The 
activation of these pathways decays with time, resulting in the attenuation and then the loss of 
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protection. Nevertheless, these pathways also stimulate the transcription of cardioprotective 
genes that induce the late protection, which occurs approximately 20-24h after the initial PC 
stimulus [28].  
Previous studies have been identified several proteins as possible mediators in the late phase of 
protection such as the iNOS [6, 29, 30, 31, 32], Cox2 [29], aldose reductase, antioxidant 
enzymes, particularly MnSOD, [33], and heat stress proteins. Among the various cellular kinases 
that are activated by various PC stimuli, PKC [34] and Src protein tyrosine kinases play an 
essential role in the development of late PC [35].  
It has now become clear, that the late protection is a complex phenotype involving multiple genes 
and can be considered as a whole genomic response initiated by various preconditioning stimuli. 
With the different tools of genomics which aims to study changes in gene expression, attention 
has turned to the exploration of the mechanism behind such multigenic phenomenon. Using large 
scale gene profiling techniques such as cDNA microarrays differential display or subtractive 
hybridization techniques, it was found that ischemic changes activate a protective genetic 
program which enables cardiomyocytes to overcome the harmful consequences of an otherwise 
lethal ischemic insult. Depre et al showed [36] in a pig ischemia model that genes from different 
cell survival pathways, including anti-apoptotic (i.e. the serine protease inhibitors plasminogen 
activator 1 and 2), cytoprotective genes (e.g. heat shock proteins) as well as cell growth 
promoters were up-regulated using gene microarray technique. Furthermore, Simkhovich et al. 
[37, 38] has found that protective genetic program was activated in rabbit and rat hearts following 
a brief episode of ischemia. They have found that transcripts, encoding the cytoprotective 
MAPKAPK-3, HSP 22, 27, 28, 70 iNOS and alpha B-crystalline, cell growth promoters (ATF-3 
and H11 kinase) were increased. Ónodi et al has identified numerous genes with different 
functions following preconditioning using cDNA microarray with 3200 rat specific genes [39]. 
These genes were involved in protein degradation, stress response (heat shock proteins), 
apoptosis, metabolic processes and various regulatory mechanisms. 
These studies have demonstrated that preconditioning mediated by short durations of reversible 
ischemia could result in the reprogramming the expression pattern of gene with diverse functions.  
For example, genes involved in stress response, such as antioxidants and heat shock proteins, 
were the most common genes which showed an altered transcription pattern in response to IPC 
[40]. Furthermore, genes encoding mitochondrial proteins and members of the survival signaling 
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or anti-apoptotic factors are also dramatically altered after IPC [40]. In our recent study, we have 
shown that cardiac pacing results in time-dependent changes in Cx43 gene and protein 
expression, which may alter gap junction function and influence arrhythmia generation during a 
subsequent ischemia and reperfusion insult [41]. 
There is no doubt that gene expression changes are important for the development of the late 
protection induced by short ischemic periods, but the transcriptional alterations in the 
antiarrhythmic adaptation induced by rapid cardiac pacing are less understood.  
 
1.4 Mechanisms involved in the delayed antiarrhythmic protection induced by rapid 
cardiac pacing 
The experimental evidence that bradykinin has an important role in the antiarrhythmic effect of 
cardiac pacing comes from previous results in anesthetized dogs. These demonstrated that 
incatibant (HOE 140), an antagonist of bradykinin at B2 receptors, attenuates the pacing-induced 
early and delayed antiarrhythmic protection [42, 43]. In the presence of incatibant, pacing the 
heart through the right ventricle increased the severity of arrhythmias and ischemia during the 
pacing protocol, and abolished the antiarrhythmic protection during coronary artery occlusion 
and reperfusion [42].  
The first evidence that NO is a key mediator not only in the early but also in the late protection 
came from studies in which the non-selective iNOS inhibitor, dexamethasone abolished the 
delayed antiarrhythmic protection resulted from rapid cardiac pacing [29]. Later this had been 
confirmed by studies using more selective inhibitors of iNOS [6, 30, 31, 44]. For example, when 
aminoguanidine [31] and AEST [6] was administered prior to the occlusion in dogs that were 
subjected to cardiac pacing 24h previously, the antiarrhythmic protection was abolished. 
Similarly, the repeated cardiac pacing-induced prolonged protection [6] as well as the heavy 
physical exercise-induced delayed antiarrhythmic effect [44] were both sensitive for selective 
(AEST) and non-selective (L-NAME) inhibitors of iNOS, indicating a role for iNOS activation in 
the development of the delayed cardioprotection.  
Since these inhibitors are not entirely selective for iNOS, for example dexamethasone inhibits 
cox-2 as well [29], whereas L-NAME interferes NO formation resulting from activation of any 
NOS enzymes [44], the role for other isoforms of NO producing enzymes in the delayed phase of 
the protection can not be ruled out.   
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Using in vitro methods, other studies have reported that the activity of constitutive calcium-
dependent NOS enzymes (eNOS and nNOS) was increased only immediately after 
preconditioning, but remained unaffected 24h later [45], whereas the mRNA of iNOS was up-
regulated and showed marked enzymatic activation only during the late phase of the protection 
[32]. They have put forth a hypothesis that NO is generated from the activation of constitutive 
NOS enzymes and induces the transcription of iNOS thereby enhances further NO generation at 
later time points (NO induced NO formation). Since in our previous studies we had only 
pharmacological evidence for the role of NO in the delayed antiarrhythmic protection we have 
now aimed to investigate this by using molecular biology approach. 
 
1.5 Aims of the study 
The objectives of the present studies were to explore the mechanism of the antiarrhythmic 
protection induced by rapid cardiac pacing by gene expression profiling. Therefore, 
 
I. In Study I, we have attempted to examine gene expression changes following ischemia and 
reperfusion in dogs subjected to rapid right ventricular pacing twenty-four hours previously. Two 
approaches were used:  
- cDNA microarray analysis which enables to identify the transcription patterns of genes 
activated by a certain intervention such as cardiac pacing, and 
- qRT-PCR by which we analyzed the transcription of 45 selected genes, which had already been 
proposed to play roles in the delayed phase of the preconditioning-induced protection. 
 
II. In Study II, the time course changes of gene expression following rapid cardiac pacing have 
been analyzed.  
 
2. MATERIALS AND METHODS 
 
2.1 Experimental protocols and surgical interventions 
Adult mongrel dogs of both sexes were used (mean body weight 20 ± 1 kg) in these studies. The 
origin and upkeep of these dogs were in accordance with the Hungarian law (XXVIII, chapter IV, 
paragraph 31) regarding large experimental animals, which conforms with the Guide for the Care 
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and Use of Laboratory Animals published by the US National Institute of Health (NIH 
Publication No. 85-23, revised 1996). 
 
2.1.1 Experimental protocols 
In Study I and II, a total of thirty-three dogs were instrumented by introducing a pacing electrode 
into the right ventricle (Figure 1).  
In Study I, three dogs served as sham paced and sham operated controls (C). In these animals, the 
pacing electrode was introduced into the right ventricle, but the dogs were not paced. Twenty-
four hours later these dogs were re-anesthetized, thoracotomised and instrumented but were not 
subjected to coronary artery occlusion. Another three sham-paced dogs, 24h after the 
instrumentation, were subjected to a 25 min occlusion of the left anterior descending (LAD) 
coronary artery. These animals served as the ischemic controls (IC). Other three dogs were paced 
on day one and 24h later were subjected to a 25 min LAD occlusion (PO group). After euthanasia 
with an intravenous overdose of the anesthetic the hearts were sectioned at the time points 
indicated by arrows (Figure 1) and tissue samples were taken for further biochemical analysis. In 
Study II, twelve animals were subjected to rapid cardiac pacing (P), whereas another twelve dogs 
served as sham-paced controls (SP). Dogs of the paced and non-paced groups were divided into 4 
further groups, each containing 3 animals. From these dogs after euthanasia with an intravenous 
overdose of the anesthetic the hearts were excised immediately (P-0h/SP-0h), six (P-6h/SP-6h), 
twelve (P-12h/SP-12h) or twenty-four (P-24h/SP-24h) hours after the pacing or sham-pacing 
procedures (Figure 1).  
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Figure 1. Experimental protocols. In Study I, relative gene expression changes were determined 
in three groups of dogs; controls were sham paced and sham operated dogs, without (C) and with 
ischemia (IC) and in paced dogs that were subjected to coronary artery occlusion and reperfusion, 
24h after pacing (PO). In Study II, the time-course changes in gene expression occurring after 
rapid cardiac pacing were determined at four time points both in the unpaced and paced dogs (P-
0h, P-6h, P-12h, P-24h). 
 
2.1.2. Cardiac pacing procedure 
The pacing procedure was performed as described previously [5]. In brief, the dogs were lightly 
anesthetized by the intravenous administration of sodium pentobarbitone (0.5 mg kg
-1
 i.v., 
Euthanyl
®
Bimeda-MTC Animal Health Inc.) and were allowed to breathe spontaneously. Arterial 
blood pressure was monitored from the left carotid artery using methods previously described in 
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detail (Kaszala et al 1996, Vegh et al 1992). Through the right jugular vein, a pacing electrode 
(CordisF4, Johnson & Johnson Company, USA) was inserted into the right ventricle such as that 
it made contact with the ventricular wall. The correct placing of the electrode was confirmed by 
recording the endocardial electrocardiogram. The dogs were then paced at a rate of 240 beats 
min
-1
 for four 5 min periods with 5 min rest intervals between the pacing stimuli. The sham-
paced controls were those in which the pacing electrode was positioned into the right ventricle, as 
described above but the dogs were not paced. The effect of pacing was followed by measuring 
changes in subendocardial ST-segment elevation immediately after cessation of pacing using the 
pacing electrode.  
 
2.1.3. Coronary artery occlusion 
Twenty-four hours later, those dogs that had been selected for coronary artery occlusion (in the 
IC and PO groups) were re-anesthetized with a mixture of α-chloralose and urethane (60 and 200 
mg kg
-1
, respectively Sigma, USA), intubated and ventilated with room air using a Harvard 
respirator (Harvard Apparatus, USA) at a rate and volume sufficient to maintain arterial blood 
gases and pH within the normal limits [2]. Body temperature was measured from the mid-
esophagus, and maintained at 37±0.5 oC by means of a heating pad. Polyethylene catheters were 
inserted into the right femoral vein and into the femoral artery for further administration of the 
anesthetic and to measure arterial blood pressure. The catheter inserted in the left carotid artery 
previously was then led to the left ventricle to measure changes in left ventricular pressure and 
dP/dt.  
A thoracotomy was performed at the fifth intercostal space and the anterior descending branch of 
the LAD was prepared for occlusion just proximal to the first main diagonal branch. Myocardial 
ischemia was induced by a 25 min occlusion of this artery as described previously (Vegh et al 
1992). The severity of myocardial ischemia was assessed by the measurement of changes in the 
degree of inhomogeneity of electrical activation and in epicardial ST-segment by means of a 
composite electrode described previously [2]. The depth of anesthesia was monitored by the 
examination of the cornea and pain reflexes as well as by the measurement of blood pressure, and 
when it was necessary a further bolus injection of the anesthetic was given. 
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2.1.4 Evaluation of ventricular arrhythmias  
Ventricular arrhythmias were assessed according to the Lambeth Conventions [46] with that 
modification as has been previously outlined [2]. In brief, the total number of VBPs, the 
incidence and number of episodes of ventricular tachycardia (defined as a run of four or more 
VBPs at a rate faster than the resting heart rate), and the incidence of VF were assessed during 
the occlusion period. 
 
2.2 Myocardial tissue sampling  
At the end of the experimental protocols the animals were given an overdose of the anesthetic, 
and the hearts were rapidly excised and placed in ice cold saline. Tissue samples were taken from 
the ischemic area (supplied by the LAD) and from the non-ischemic area (supplied by the LCX) 
for further analysis.  
 
2.3 Isolation of RNA 
Tissue samples from both the ischemic and non-ischemic myocardial regions were powdered in 
liquid nitrogen and 25 mg was used for RNA isolation. Then total RNA was purified with the 
RNeasy Fibrous Tissue Mini Kit (Qiagen, Germany) according to the manufacturer’s instruction. 
The integrity of RNA was assessed by gel electrophoresis and the concentration of total RNA was 
determined by UV-photometry. DNaseI digestion was also performed to avoid the potential 
genomic DNA contamination. The RNA preparations from 3 dogs in each group were pooled 
together. The total RNA preparations were used for microarray analysis and qRT-PCR 
measurements.  
 
2.4 Microarray analysis 
The microarray analysis was performed as described by [47]. In brief, human cDNA microarray 
containing 3200 human cDNA clones was used for the hybridization. For probe preparation, 2 µg 
of total RNA was reverse transcribed using poly-dT-primed Genisphere Expression Array 350 
Detection Kit system (Genisphere, USA) according to the manufacturer’s instructions. Both 
cDNA hybridization and capture reagent hybridization were carried out in a Ventana 
hybridization station (Ventana discovery, USA) using the “antibody” protocol. The first 
hybridization was performed at 40 
0
C for 6 hours in “FGL2” hybridization buffer (10xDenhart 
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solution, 0.25 M sodium phosphate buffer pH 7.0, 1mM EDTA, 1x SSC, 0.5% SDS), then 2.5 µl 
each of Cy5 and Cy3 capture reagents in 200 µl “Chiphyb” hybridization buffer (Ventana) were 
added to the slides and incubated at 42 
0
C for 2 hours. After hybridization, the slides were 
washed twice in 0.2 X SSC at RT for 10min, then dried and scanned.  
Each array was scanned under a green laser (532 nm) (for Cy3 labeling) and under a red laser 
(660 nm) (for Cy5 labeling) using a ScanArray Lite (GSI Lumonics, Billerica, MA, USA) 
confocal fluorescent scanner with 10 μm resolution. Image analysis was performed by 
ScanAlyze2 software (http://www.microarrays.org/software.html). Each spot was defined by 
manual positioning of a grid of circles over the image. The average pixel intensity and the local 
background of each spot were determined. To measure the ‘expression ratio’, MRAT (denotes the 
median of the set of background-corrected single pixel intensity ratios of the two channels within 
the spot) was determined. This average expression ratio for all genes on the array was normalized 
to 1.0. For background corrections those data were calculated as negatives where the average 
intensity of the spot was smaller than two times the average background of the same area. 
Significant spots have more than 0.55 CHGTB2 values (denotes fraction of pixels in the spot 
greater than background) in both Cy3 and Cy5 channels. To reduce the number of false positive 
or false negative ratios, two probes were generated from each RNA pool: a Cy5-labeled and a 
Cy3-labeled one in order to perform replicate experiments. Replica spots (on the same array) and 
replica experiments (two different arrays) resulted in four data points for every gene. Those spots 
were excluded from further analysis when ratios of the replica spots had a more than two-fold 
difference. The same restriction was applied for the average ratios of the replica experiments. 
 
2.5 Quantitative Real-Time PCR (qRT-PCR) 
Quantitative RT-PCR was performed by ABI7000 instrument (Applied Biosystems, Carlsbad, 
USA) with gene-specific primers to monitor gene expression changes. Two μg of total RNA from 
each sample was reverse transcribed using ImPromII reverse transcriptase (Promega, USA) in the 
presence of poly(dT) primers at 42 
o
C for 1h. After this, cDNAs were diluted in 50 μl water, and 
1 μl of this reaction mix was used as template for qRT-PCR. This was performed using the 
SYBRGreen protocol with SYBR Green PCR Master Mix with passive reference dye (Applied 
Biosystems, Carlsbad, USA) according to the manufacturer’s instructions at a final primer 
concentration of 500nM. The primers were designed using the PrimerExpress 2.0 (Applied 
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Biosystems, Carlsbad, USA) and verified by NCBI-BLAST. Relative expression ratios were 
calculated as normalized ratios to HPRT and to tubulin. A non-template control sample was 
applied for each run to control the genomic DNA contaminations of the template. Melting 
temperature analysis has been performed after each reaction to assess the quality of the reaction.  
The final relative gene expression changes were calculated as delta-delta Ct values. Genes with 
expression values lower than 0.5 or higher than 1.5 were considered to be down or up-regulated 
(the values correspond to an interval of log2=-1 and log2=0.6). All the PCRs were performed in 
triplicate with two parallel runs for each reaction. All data were expressed as mean ± SD. 
 
2.6 Immunoblot analysis 
Transmural tissue samples from both the ischemic and non-ischemic regions of the left ventricle 
were powdered in liquid nitrogen and stored at -80°C. The samples were then homogenized in ice 
cold lysis buffer (20 mM Tris-HCl pH 7.4, 250 mM sucrose, 0.1% protease inhibitor cocktail, 
Sigma) and centrifuged at 2000g for 15 min. The supernatant was used either as a total protein 
fraction or centrifuged at 50000 g for 45 min and the pellet was re-suspended in ice cold lysis 
buffer and used as the membrane fraction. Protein concentrations were determined by the method 
of Lowry. Total protein samples of 100ug and membrane protein extracts of 80ug were separated 
on 8% polyacrylamide gels and transferred to PVDF membranes (Millipore). After blocking in 
5% non-fat milk (for one hour at room temperature), the membranes were incubated with two 
different primary antibodies. Anti-eNOS (BD Transduction Laboratories
TM
) was used to measure 
the protein expression of eNOS (in a dilution of 1:3000) and anti-phospho-eNOS (peNOS, 
Ser1177, BD Transduction Laboratories
TM
) to detect the activation of eNOS (in a dilution of 
1:1000) by the Akt/PI3 kinase pathway. This was followed by one hour incubation of HRP-
conjugated goat anti-rabbit secondary antibody at room temperature (in a dilution of 1:8000). 
Blots were developed with ECL plus kit (GE Healthcare) and exposed to X-ray films (Amersham 
Biosciences). Band densities were measured using ImageJ software (NIH). For the precise 
comparison of the three parallel western blots, each pixel intensity was normalized to the highest 
value on each blot. For verification of equal loading, Coomassie staining was performed. Values 
are mean ± S.E.M. *P<0.05 vs. SP group (Bonferroni correction). 
 
 
19 
3. RESULTS 
3.1 Gene expression changes in control and paced dogs subjected to coronary artery  
occlusion and reperfusion twenty-four hours later 
cDNA microarray analysis was performed in order to identify gene expression changes in the 
pacing-induced delayed antiarrhythmic protection. The expression values of the ischemic and 
preconditioned groups were compared to those obtained from the sham paced, sham operated 
control dogs. Their relative expression ratios are shown in Table 1. The data obtained from cDNA 
microarrays were confirmed by qRT-PCR analysis.  
Out of the studied 3200 cDNAs four genes were down- and five genes were up-regulated in the 
ischemic group compared to the control dogs. Compared to the IC group, cardiac pacing resulted 
in an enhanced expression of 19 genes and lower expression of 4 genes. These genes with altered 
transcription rate encode transcription factors, ion channels and members of signal transduction 
pathways. Some of these, for example MEF2A and PDE4D9 were not significantly changed in 
response to myocardial ischemia, but were up-regulated following rapid cardiac pacing. In 
contrast, three genes (14-3-3zeta, AVPR1, AVPR2), that showed higher expression in the 
ischemic controls, were either not changed (14-3-3zeta) or down-regulated (AVPR1, AVPR2) in 
dogs paced 24h previously. The abbreviations of this section can be found in the Table 1. 
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Categories Gene name Accession IC/C PO/IC 
     
ion channel/transcription factors chloride intracellular channel protein 1 (NCC27) XM_532079 0.37 2.36 
 rearranged L-myc fusion (ZN-15 related zinc finger protein) XM_532543 1.17 0.54 
 myocyte enhancer-binding factor 2 (MEF2) XM_536298 1.14 4.28 
     
metabolic enzyme alcohol dehydrogenase 1C, gamma polypeptide (ADH1C) XM_535667 0.65 3.83 
     
signal transduction prolactin receptor (PRLR) XM_536502 1.20 1.88 
 arginine vasopressin receptor 1 (VR1)  XM_538263  2.16 0.43 
 arginine vasopressin receptor 2 (VR2) NM_001003177 2.12 0.45 
 protein tyrosine phosphatase, receptor type, J precursor (PTPRJ) XM_540737 0.52 0.38 
 tumor necrosis factor receptor member 10A precursor (TRAIL-R1)  XM_543245 2.84 1.45 
 interleukin-1 receptor-associated kinase 1 (IRAK-1) XM_549367 0.54 2.69 
 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein,  
zeta polypeptide (14-3-3 zeta) 
XM_533072 1.89 0.53 
 cAMP-specific phosphodiesterase variant (PDE4D9)  XM_535243 0.65 3.83 
 transforming growth factor, beta 2 (TGFB2) XM_545713 0.97 1.88 
 phosphorylase b kinase gamma catalytic chain, skeletal muscle isoform (PHKG1) XM_546902 0.53 2.24 
     
others ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3GAL1) XM_539171 1.40 1.85 
 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 XM_543872 0.83 0.50 
 granzyme K precursor  XM_546318 1.07 1.88 
 zinc finger protein, X-linked (ZFX) AF027765  1.01 1.91 
 translocation associated membrane protein 1 (TRAM1) NM_001003267 0.43 2.02 
 phosphatidylinositol glycan, class Q isoform 2  XM_547216 0.30 3.34 
 A-kinase anchor protein 6 (mAKAP) XM_547766 0.81 2.28 
 midline 1 isoform alpha  XM_548857 0.36 4.10 
 necdin XM_545810 0.45 2.49 
 gastric inhibitory polypeptide receptor precursor (GIPR) XM_541554 1.61 1.80 
 WD-repeat protein 26 (WDR26) XM_537237 1.05 1.88 
 GPATCH8 G patch domain containing 8 (GPATCH8) XM_537619 0.72 1.93 
 
Table 1. Gene expression changes following cardiac pacing by cDNA microarray. The expression values were calculated from the intensity ratios 
obtained from the scanning analysis of the cDNA microarray as described in the section of Materials and Methods. (The values labeled with red 
indicate up-regulation while the data labeled with blue indicate down-regulation). Each experiment was performed twice. 
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3.2 Gene expression changes following cardiac pacing determined by qRT-PCR 
analysis 
QRT-PCR was performed to study 45 genes which have previously been identified as potential 
mediators or important members of the preconditioning-induced cardioprotection. Thus, genes 
encoding gap junction proteins (Cx40; Cx43; Cx45) NO producing enzymes (iNOS, eNOS, 
nNOS), cyclooxygenases (COX1, COX2), antioxidants (CAT, Mn-SOD, Cu/Zn-SOD), anti-
apoptotic and apoptotic proteins (BAX, BAK, Casp3, Casp9), heat shock proteins (HSP27, 
HSPA8), cytokines (IL-6, TNFα); growth factors (TGFβ, TGFBR2), transcription factors (c-fos), 
members of different signal transduction pathways, such as different isoforms of the protein 
kinase C (PKCα; PKCδ, PKCε), of the JNKs (JNK1,2,3) and of the sGCs (sGCα1/β1, sGCα2/β2) 
were examined (Table 2).  
Out of the 45 studied genes, six exhibited significant down-regulation and 16 showed up-
regulation in response to myocardial ischemia when compared to the control dogs. Their 
expression ratios changed either to the opposite (11) or showed no alteration (10) in the PO group 
(Table 2). Among these nNOS, HSP70, PKCα, JNK1, GSK3α, GYS1, BDKRB1 showed up-
regulation, and BAX, BAK and casp3 down-regulation after rapid cardiac pacing. 
Figure 2, 3 and 4 illustrate some of these genes from different functional categories, which 
showed expression changes in response to ischemia and/or preconditioning. The abbreviations of 
this section are listed in the Table 2. 
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Categories Gene name Accession IC/C PO/IC 
     
gap junction 
proteins 
gap junction protein, alpha 5, 40kDa 
(Cx40) 
NM_005266 0.29 (0.06) 1.17 (0.21) 
 gap junction protein connexin 43 (Cx43) AY462223   1.08 (0.08) 0.83 (0.11) 
 gap junction protein, alpha 7, 45kDa 
(Cx45) 
NM_005497 1.10 (0.41) 3.64 (2.79) 
     
NO production  endothelial nitric oxide synthase (eNOS) AF400594   2.34 (0.68) 0.62 (0.05) 
 inducible nitric oxide synthase (iNOS) NM_001003186 1.79 (0.23) 0.58 (0.03) 
 neuronal nitric oxide synthase (nNOS) HSU17327 0.80 (0.07) 2.16 (0.46) 
     
antioxidants catalase (CAT) NM_001002984 1.06 (0.08) 0.29 (0.12) 
 Cu/Zn superoxide dismutase (Cu/Zn-SOD)  AF346417 0.83 (0.09) 0.70 (0.07) 
 Mn superoxide dismutase (Mn-SOD) Y00985 2.80 (1.71) 1.08 (0.50) 
 cytochrome C oxydase T19137 1.54 (0.11) 0.35 (0.08) 
     
miscellaneous cyclooxygenase-1 (COX1) NM_000962 1.02 (0.16) 0.95 (0.12) 
 cyclooxygenase-2 (COX2) NM_001003354 1.04 (0.41) 1.23 (0.43) 
 matrix metalloproteinase 2 (MMP2) BC002576 0.30 (0.11) 1.96 (0.19) 
     
apoptotic genes BCL2-associated X protein (BAX) NM_001003011 1.85 (0.17) 0.28 (0.06) 
 Bcl-2 antagonist/killer protein (BAK) DQ002813 1.50 (0.02) 0.24 (0.04) 
 caspase 3 apoptosis-related cysteine 
  peptidase (CASP3)  
NM_001003042 2.23 (0.50) 0.37 (0.09) 
 caspase 9 apoptosis-related cysteine 
  peptidase (CASP9)  
DQ116956 2.51 (0.36) 0.98 (0.07) 
     
heat shock proteins heat shock 27kDa protein 1 (HSP27) NM_001540 1.88 (0.05) 0.45 (0.05) 
 heat shock 70kDa protein 8 (HSP70) NM_006597 1.82 (0.18) 2.77 (0.65) 
 heat shock 70kDa protein 1A (HSPA1A) NM_005345 2.68 (0.56) 0.56 (0.09) 
     
cytokines tumor necrosis factor alpha (TNFα) NM_001003244 0.60 (0.08) 0.46 (0.04) 
 interleukin-6 (IL-6)  U12234 0.49 (0.04) 4.09 (0.94) 
     
growth factors transforming growth factor beta 1 (TGFβ1) NM_000660 3.43 (0.98) 0.20 (0.02) 
 transforming growth factor, beta receptor II NM_003242 0.89 (0.16) 0.50 (0.02) 
     transcription 
factors 
nuclear factor of kappa light polypeptide 
gene (NFλB1) 
NM_003998 1.11 (0.22) 1.14 (0.30) 
 c llular oncogene c-fos V01512 0.30 (0.11) 1.45 (0.24) 
     
signal transduction protein kinase C, delta (PKCδ) NM_001008716  2.65 (0.55) 0.37 (0.07) 
 protein kinase C, alpha (PKCα) NM_002737 0.95 (0.15) 2.57 (0.61) 
 protein kinase C, epsilon (PKCε) NM_005400 1.66 (0.20) 0.53 (0.07) 
 mitogen-activated protein kinase 8 (JNK1) NM_139049 0.83 (0.10) 3.31 (0.07) 
 mitogen-activated protein kinase 9 (JNK2) NM_139070 0.76 (0.10) 0.93 (0.03) 
 mitogen-activated protein kinase 10 (JNK3) BC035057 1.26 (0.37) 1.19 (0.39) 
 glycogen synthase kinase 3 alpha (GSK3α) BC027984 0.45 (0.08) 1.94 (0.32) 
 glycogen synthase kinase 3 beta (GSK3β) BC000251 10.14 (1.03) 0.73 (0.06) 
 glycogen synthase 1 (muscle) (GYS1) NM_002103 2.07 (0.13) 3.35 (1.09) 
 muscle glycogen phosphorylase (PYGM)  AF066859 1.30 (0.29) 1.14 (0.15) 
 protein phosphatase 2 (PP2A) BC032954 1.04 (0.08) 0.54 (0.05) 
 adenylate cyclase 6 (AD6) BC064923 1.29 (0.16) 0.80 (0.11) 
 guanylate cyclase soluble, alpha1 (GCα1) NM_000856 1.38 (0.33) 1.03 (0.21) 
 guanylate cyclase, soluble, beta1 (sGCβ1) NM_000857 0.98 (0.11) 0.57 (0.02) 
 guanylate cyclase soluble, alpha2 (sGCα2) NM_000855 2.36 (0.27) 0.35 (0.07) 
 guanylyl cyclase soluble, beta 2 (sGCβ2) AF038499 1.19 (0.19) 0.50 (0.07) 
 natriuretic peptide receptor A (NPR1) NM_000906 1.20 (0.11) 0.79 (0.09) 
 bradykinin receptor B1 (BDKRB1) NM_000710 0.43 (0.08) 4.91 (2.80) 
 bradykinin receptor B2 (BDKRB2)  AY275465 9.08 (9.36) 0.25 (0.12) 
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Table 2. Gene activity changes 24h after cardiac pacing in dogs subjected to coronary artery 
occlusion and reperfusion. The 45 genes examined were divided into different groups according 
to the function of proteins they encode. Genes with expression values lower than 0.5 or higher 
than 1.5 were considered to be down or up-regulated. Values are means ± SD (indicated in 
brackets) of three parallel qRT-PCR reactions. (Values labeled with red indicate up-regulation 
while the data labeled with blue indicate down-regulation).  
 
3.3 Time-course changes in gene expression following cardiac pacing in dogs 
In order to assess whether cardiac pacing induces time-dependent changes in gene expression 
occurring over a period of 24h which elapses between the pacing stimulus and the appearance of 
the delayed effect, the transcription of 29 genes were analyzed immediately, 6, 12 and 24 hours 
after cardiac pacing. Table 3 summarizes the gene expression changes observed at various time 
intervals after cardiac pacing. The results are expressed as ratios of gene expression data obtained 
from the time-matched sham-paced control hearts. 
There were eight genes which were immediately up-regulated after the cessation of pacing. These 
genes encode HSP90, MnSOD, Bcl-2, PKCε, ERK1, sGCα1, sGCβ1, sGCα2. There were six 
genes which exhibited early down-regulation following the pacing stimulus, such as CAT, casp3, 
casp9, GSK3β and MMP9. Of these early up- or down-regulated genes, MnSOD, PKCε, casp3 
and casp9, GSK3β and MMP9 remained unchanged (i.e. up and down-regulated) at almost all 
time-points, whereas the others, like HSP90, ERK1, Bcl-2 and sGC isoforms, showed biphasic 
transcriptional changes; i.e. after the initial up-regulation these genes were down-regulated 
(mostly at 6h) but up-regulated again around 12 and 24h (Table 3). There were also genes, such 
as those encode NO producing enzymes eNOS, iNOS and the gap junction forming protein Cx43, 
which exhibited significant up-regulation only 12h after the cessation of pacing (Table 3). 
Surprisingly, the expressions of genes responsible for the production of mitochondrial proteins, as 
well as Cox2, were not significantly altered.  
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Table 3. Time-course changes in gene expression following cardiac pacing in dogs. The 29 genes examined were divided into different groups 
according to their functions. Genes with expression values lower than 0.5 or higher than 1.5 were considered to be down or up-regulated. Values are 
means ± SD (indicated in brackets) of three parallel qRT-PCR reactions. (The values labeled with red indicate up-regulation while the data labeled 
with blue indicate down-regulation.) 
Categories Gene name Accession P-0h/SP P-6h/SP P-12h/SP P-24h/SP 
       
heat shock proteins heat shock 27kDa protein (HSP27) NM_001003295 0.50 (0.01) 0.36 (0.07) 0.92 (0.21) 1.08 (0.37) 
 heat shock 70kDa protein (HSP70) NM_006597 0.99 (0.72) 0.19 (0.13) 0.69 (0.48) 0.32 (0.16) 
 heat shock 90kDa protein (HSP90) NM_001017963.2 1.78 (0.19) 0.85 (0.17) 1.50 (0.25) 1.11 (0.31) 
        
gap junctions connexin 43 (Cx43) NM_001002951 1.43 (0.18) 0.40 (0.10) 2.20 (0.44) 1.15 (0.28) 
       
antioxidants catalase (CAT) NM_001002984 0.17 (0.13) 0.25 (0.12) 0.89 (0.70) 0.87 (0.46) 
 Mn superoxide dismutase (MnSOD) NM_000636 2.30 (0.46) 1.80 (0.26) 1.61 (0.15) 2.02 (0.50) 
       
NO production endothelial nitric oxide synthase (eNOS) NM_001003158 0.67 (0.07) 1.09 (0.06) 2.19 (0.53) 0.59 (0.11) 
 inducible nitric oxide synthase (iNOS) NM_001003186 1.47 (0.45) 1.15 (0.22) 2.43 (0.27) 0.99 (0.21) 
       
apoptosis apoptosis-related cysteine peptidase 3 (casp3) NM_001003042 0.36 (0.09) 0.33 (0.13) 0.32 (0.12) 1.28 (0.08) 
 apoptosis-related cysteine peptidase 9 (casp9)  XM_847070 0.18 (0.16) 0.15 (0.11) 0.32 (0.05) 1.23 (0.22) 
 BCL2-associated X protein (BAX) NM_001003011 0.72 (0.28) 0.32 (0.02) 0.74 (0.38) 1.15 (0.22) 
 B-cell CLL/lymphoma 2 (Bcl2) NM_001002949 2.78 (0.99) 0.45 (0.15) 1.62 (0.54) 2.66 (1.02) 
       
signal transduction protein kinase C, alpha (PKCα) NM_002737 1.42 (0.39) 0.87 (0.36) 2.15 (0.40) 1.90 (0.23) 
 protein kinase C, delta (PKCδ) NM_001008716 1.05 (0.01) 0.57 (0.14) 1.44 (0.32) 1.31 (0.23) 
 protein kinase C, epsilon (PKCε) NM_005400 6.73 (2.43) 1.77 (0.32) 2.27 (0.31) 2.08 (0.37) 
 glycogen synthase kinase 3 beta (GSK3β) NM_002093 0.37 (0.10) 0.34 (0.08) 0.71 (0.30) 0.44 (0.09) 
 extracellular signal-regulated kinase 1 (ERK1) NM_002746 2.32 (0.37) 0.49 (0.24) 0.72 (0.42) 2.47 (0.78) 
 extracellular signal-regulated kinase 2 (ERK2) NM_002745 0.98 (0.35) 0.95 (0.36) 1.26 (0.66) 0.59 (0.34) 
 guanylate cyclase soluble, alpha 1 (sGCα1) NM_001018035 1.71 (0.14) 1.44 (0.26) 1.12 (0.21) 2.44 (0.16) 
 guanylate cyclase soluble, beta 1(sGCβ1) NM_001018034 2.97 (0.53) 2.51 (0.64) 1.27 (0.19) 2.60 (0.51) 
 guanylate cyclase soluble, alpha 2 (sGCα2) NM_000855 2.21 (0.81) 1.18 (0.07) 1.62 (0.11) 2.41 (0.90) 
       
mitochondria cytochrome c (CytC) NM_001197045 1.05 (0.25) 0.85 (0.21) 0.79 (0.22) 1.00 (0.54) 
 ATP synthase, Fo complex, subunit F6 NM_001003703 1.48 (0.14) 0.93 (0.30) 0.64 (0.05) 0.51 (0.09) 
 cytochrome c oxidase subunit Va (COX5A) NM_004255 1.38 (0.15) 0.82 (0.05) 0.02 (0.28) 1.16 (0.07) 
 NADH dehydrogenase Fe-S protein2, 49kDa NM_001166159 1.33 (0.19) 0.59 (0.06) 0.80 (0.07) 0.76 (0.09) 
 NADH dehydrogenase Fe-S protein1, 75kDa NM_005006 1.05 (0.18) 0.65 (0.16) 0.46 (0.08) 0.52 (0.07) 
       
others matrix metalloproteinase 2 (MMP2) NM_004530 0.63 (0.19) 0.65 (0.09) 1.04 (0.18) 0.73 (0.02) 
 matrix metalloproteinase 9 (MMP9) NM_001003219 0.06 (0.08) 0.17 (0.04) 1.08 (0.38) 0.59 (0.31) 
 cyclooxygenase-2 (Cox2) NM_001003354 0.19 (0.09) 0.28 (0.14) 0.87 (0.41) 0.27 (0.15) 
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Some of the results summarized in Table 2 and Table 3 are also illustrated in figures (Figure 2, 3 
and 4) by selecting those genes which have shown significant transcription alterations following 
cardiac pacing, and also after the 25 min of coronary artery occlusion and reperfusion may have 
essential functional role in the delayed cardioprotection afforded by preconditioning.  
Figure 2. The effect of rapid cardiac pacing and ischemia/reperfusion on the expression of 
genes involved in apoptosis. Values are means ± SD. The lines indicate the interval between 0.5 
and 1.5 fold of regulation. 
 
Figure 2 shows that cardiac pacing significantly down-regulated the transcription of genes which 
are involved in apoptosis (casp3, casp9 and Bax) immediately (0h), 6 and 12h after cardiac 
pacing, but at 24h the expression of these genes was not significantly different from the non-
paced controls. In contrast, pacing enhanced, at each time point, except 6h, the expression of 
gene encoding the anti-apoptotic Bcl-2 (Figure 2). Myocardial ischemia also altered the 
expression of casp3, casp9 and Bax. These exhibited significant up-regulation compared to the 
sham group and their expression ratios changed either to the opposite (casp3 and Bax) or showed 
no alteration (casp9) after cardiac pacing (Figure 2). 
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Figure 3. The effect of rapid cardiac pacing and ischemia/reperfusion on the expression of genes encoding proteins involved in 
signal transduction pathways. Values are means ± SD. The lines indicate the interval between 0.5 and 1.5 fold of regulation. (Note: 
ERK1 and ERK2 were not involved in Study II.) 
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The time-course pattern of genes encoding proteins involved in signal transduction showed large 
variation. Of these genes only PKCε exhibited enhanced transcription in response to rapid cardiac 
pacing at each time point. PKCα was only up-regulated at 12 and 24h whereas, the expression of 
PKCδ remained virtually unchanged (Figure 3). ERK1 showed an early (0h) and late (24h) up-
regulation, while GSK3β was down-regulated at almost all the measured time points. Genes 
encoding the isoforms of sGC were significantly up-regulated immediately, and 24h after the 
cessation of the pacing stimulus (Figure 3). In response to ischemia, GSK3β showed a significant 
down-regulation while the other genes were not altered. These genes in the PO group showed no 
significant changes except for PKCα which was up-regulated when compared to the ischemic 
controls. 
 
Figure 4. The time-course changes in expression of genes which encode eNOS, iNOS, 
MnSOD enzymes as well as Cx43 and their alterations at the time of delayed PC. Values are 
means ± SD. The lines indicate the interval between 0.5 and 1.5 fold of regulation. Myocardial 
ischemia up-regulated the expression of MnSOD, iNOS and eNOS but the relative expression 
ratios of these genes were not altered when rapid cardiac pacing was performed 24h earlier. 
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The genes responsible for the transcription of eNOS, iNOS were significantly up-regulated only 
12h after pacing. (Figure 4). In contrast, the mRNA expression of MnSOD was up-regulated at all 
time points. The transcription level of Cx43 down-regulated at 6h but up-regulated 12h after 
pacing and, as we have described previously, these changes in Cx43 gene expression were in 
association with arrhythmia generation resulting from ischemia and reperfusion [41].  
 
3.4 Time-course changes in eNOS protein content and activation 
We have performed experiments in which, using the sham-paced control and paced heart 
samples, the time course of eNOS protein content and activity were determined by Western blot 
analysis (Figure 6). The results clearly show that compared with the non-paced controls, in the 
paced dogs eNOS protein content was significantly increased only 24h after the pacing stimulus 
(Figure 5a), whereas the activity of this enzyme (assessed by measuring the phosphorylated form) 
was increased twice; i.e. immediately and 24h after pacing (Figure 5b). 
 
Figure 5. Time-course changes in eNOS protein content (A) and activation (B) determined 
at various time intervals after rapid cardiac pacing by Western blot. Values are mean ± 
S.E.M. *P<0.05 vs. SP group (Bonferroni correction). 
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4. DISCUSSION 
 
4.1 New findings 
 
I. We have identified 23 genes with altered expression induced by cardiac pacing in a large 
animal model of ischemia and reperfusion. Cardiac pacing resulted in an enhanced expression of 
19 genes and lower expression of 4 genes. The genes with altered transcription rate encode 
transcription factors, ion channels and members of signal transduction pathways. Some of these, 
for example MEF2A or mAKAP, has been firstly demonstrated to be significantly up-regulated 
during the pacing induced protection. 
 
II. We have proved that rapid right ventricular pacing is associated with altered expression of 
genes involved in the delayed protection. Forty-five genes were selected which have previously 
identified as mediators or important members of the PC induced cardioprotection. Out of these 
genes, six exhibited significant down-regulation and 16 showed up-regulation in response to 
myocardial ischemia when compared to the control dogs. Their expression ratios changed either 
to the opposite (11) or showed no alteration (10) in the PO group. Among these nNOS, HSP70, 
PKCα, JNK1, GSK3α, GYS1, BDKRB1 showed up-regulation, and BAX, BAK and casp3 down-
regulation after rapid cardiac pacing. 
 
III. We are the first to show that cardiac pacing induces time course changes in gene expression 
during the time interval which elapses between the PC stimulus and the appearance of the 
delayed protection. There were 8 genes which were up-regulated immediately after the cessation 
of pacing (HSP90, MnSOD, Bcl-2, PKCε, ERK1, sGCα1, sGCβ1, sGCα2) and there were 6 
genes which exhibited an early down-regulation following the pacing stimulus (CAT, casp3, 
casp9, GSK3β, MMP9 and Cox2). Some of these early up- or down-regulated genes remained 
unchanged (i.e. up and down-regulated, MnSOD, PKCε, casp3 and casp9, GSK3β and MMP9) at 
almost each observed time-points, whereas others, like ERK1, Bcl-2 and sGC isoforms, showed 
biphasic transcriptional changes; i.e. after the initial up-regulation these genes were down-
regulated (mostly at 6h) but were up-regulated again around 12 and 24h. There were also genes, 
eNOS, iNOS and Cx43, which exhibited significant up-regulation only 12h after the pacing 
stimulus. 
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IV. We propose that an increase in eNOS protein expression and activity, besides the increased 
iNOS activation, may also play a role in NO production which mediates the late phase of the 
protection. 
 
4.2. Changes in transcription levels of different genes after delayed PC by cDNA 
microarray.  
In the last few years, cDNA microarrays [39, 48, reviewed by 40] or other large-scale expression 
profiling technologies, such as subtractive hybridization [36] or RDA [49] are increasingly used 
to determine transcriptional profiles induced by PC in different animal models. In order to 
understand the different genomic responses, the knowledge of cDNA sequences is required. Since 
commercial microarrays, printed with thousands of known cDNAs, are primary available for 
rodents (rats or mice) large scale genomic analysis have been performed in these animal models 
to investigate gene expression profiles occurring during ischemia and reperfusion or after 
preconditioning [37, 38, 39.]. Only few studies aimed to examine the preconditioning-induced 
genomic responses in large animals such as pigs and dogs. For example, in dogs, using cDNA 
RDA analysis, Zubakov et al. have found that genes involved in inflammatory response were 
highly up-regulated during the late phase of preconditioning [49]. In a porcine model, induction 
of genes encoding transcription factors, heat shock proteins, calcium-handling proteins and 
growth factors have been found in response to preconditioning [50].  
Thus, one of the aims of these studies was to find a relationship between the antiarrhythmic effect 
and the gene expression changes that occur in dogs subjected to coronary artery occlusion and 
reperfusion 24h after rapid cardiac pacing. To achieve this, microarray analysis was performed 
with 3200 cDNAs and the results were confirmed by qRT-PCR.  
Among the genes examined, MEF2A showed significant up-regulation during the late phase of 
the protection when compared to the ischemic controls (Table1). The transcription factor encoded 
by this gene belongs to the MEF2 family which controls vascular development [51, 52]. The 
enhanced transcription of this gene supports those previous findings that ischemic PC induces 
angiogenesis through VEGF mediated signaling and that the target gene of this pathway is a 
transcription factor from the MEF2 family [53, 54]. Another gene, TGFβ2 also showed a higher 
expression at the time of the appearance of the late phase of the protection when compared to the 
ischemic controls (Table1). This is in accordance with a previous study in which four repetitive 
cycles of coronary artery occlusion have been used to stimulate vascular growth [55] and found 
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that TGFβ was significantly up-regulated 48 h after this preconditioning stimulus. These findings 
might indicate that cardiac pacing induces processes which are involved in vascular growth. 
Another gene which was significantly up-regulated following pacing was PDE4D9. This encodes 
an isoform of a phophodiesterase enzyme responsible for cAMP degradation in cardiac myocytes 
[56] (Table1). In rat isolated and perfused hearts, ischemic PC increased tissue cAMP level, 
which was normalized upon reperfusion, whereas PDE activity showed opposite changes; i.e. 
reduced during ischemia and increased following reperfusion [57]. Furthermore, the cAMP-
dependent PDE activities were higher throughout a 25 min sustained ischemia in the 
preconditioned than in control hearts and this was accompanied by a significantly less 
accumulation of cAMP in the PC hearts. The reduction in cAMP may play a role in the 
antiarrhythmic effect by decreasing the activity of the PKA and thereby by reducing calcium 
influx through L-type calcium channels. The role of cGMPs in the regulation of PDE4 
phosphodiesterases is not clear either in the early or the delayed phase of protection. In rat 
isolated hearts, using cDNA microarray, a considerable induction in the expression of a cGMP 
phosphodiesterase (PDE9A1) has been found following preconditioning [39], suggesting that 
PDEs may play an important trigger and mediator role in the early and in the delayed 
cardioprotection.  
Another gene that showed enhanced transcription during the delayed phase of the pacing-induced 
protection is mAKAP (Table1). This protein is an anchoring protein which connects cAMP-
binding proteins, such as, PKA, EPAC1 and the phosphodiesterase PDE4D3 to form 
macromolecular complexes [58]. This complex plays an important role in the regulation of the 
cAMP-PKA signaling pathway by anchoring these proteins to different cell organelles. This of 
our finding is the first to demonstrate that the expression of an anchoring protein is altered after 
preconditioning. Similarly, genes encoding V1 and V2 receptors have not been examined in 
relation to PC. We have found that these genes were down-regulated after cardiac pacing and 
showed an enhanced expression in response to ischemia.  
In summary, among the 3200 cDNAs that have been examined, only 10 genes showed altered 
expression in response to the acute ischemic and reperfusion insult, whereas 19 genes to rapid 
cardiac pacing. One of the reasons for these limited results might be that at the time of the 
experiments genome-wide chips were not available for large animals, such as dogs or pigs. Thus, 
we used the human cDNA library for the analysis of microarrays which certainly limits the 
number of positive signals in the gene expression analysis, despite the high homology between 
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the human and canine genome. However, using a human cDNA microarray with 3200 genes we 
were able to follow the expression changes of more genes than those of the previous studies.  
Another limitation of the study is that the cDNA microarray analysis provides information only 
about the mRNA level of genes but it does not reflect the expression or the function of proteins 
that have certainly produced and possibly acted at the time of sampling. This might also explain 
that only a limited number of genes have been found with altered expression during the late phase 
of the protection induced by cardiac pacing.  
The results of these previous studies have prompted us to perform further investigations, in which 
the time course changes of gene expression were analyzed during a 24h period, which elapses 
between the preconditioning stimulus and the test ischemia. Also, some proteins for example 
Cx43 in a previous and eNOS in this current study were also examined to obtain information on 
their expression changes at the protein level due to cardiac pacing. 
 
4.3 Effects of rapid cardiac pacing on gene expression changes 
In this study, numerous genes were selected for RT-PCR analysis from various functional 
categories that had been previously shown to relate to the delayed protection (Table 2 and Table 
3). Furthermore, this is the first study which has attempted to examine the sequence of gene 
expression changes following a PC stimulus. 
Previous results from various animal models confirmed the involvement of NOS enzymes (iNOS; 
eNOS; nNOS), antioxidant enzymes (Cu/Zn-SOD; MnSOD; CAT), cyclooxygenases (COX1; 
COX2), and heat shock proteins (HSPs) in the delayed cardioprotective effect of preconditioning.  
Previous results suggested that the antioxidant factor MnSOD has a particular role both in the 
early and the delayed phase of protection [33, 59, 60]. The transcription of this gene was 
significantly enhanced in response to cardiac pacing at all the observed time points (Figure 4). 
Compared to the sham-paced and sham-operated controls, the expression of this gene was also 
significantly up-regulated after myocardial ischemia and it was not significantly altered by 
cardiac pacing (Figure 4). Das et al also found that repeated ischemia and reperfusion caused an 
immediate up-regulation in the expression of MnSOD in isolated buffer-perfused rat hearts [59]. 
MnSOD content was also increased with a peak at 24h after four 5 min episodes of regional 
ischemia and reperfusion in canine myocardium [33]. This finding supports the proposed 
parallelism between the induction of MnSOD and the protection, although a direct evidence for a 
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cause-and effect relationship between the up-regulation of MnSOD and the pacing-induced 
protection has not yet been established.  
Interestingly, one of the other examined antioxidant factors CAT, was down-regulated at the early 
time points after cardiac pacing, and also after a 25 min period of ischemia preceded by overdrive 
pacing 24h before (Table 2 and 3). This result is in contrast with other studies using isolated 
Langendorf-perfused hearts in which an enhanced transcription for this gene has been found [59, 
60]. However, these results were not confirmed by in vivo studies; i.e. neither catalase in dogs 
[33] nor other antioxidant enzymes in conscious pigs [61] were up-regulated in the time of the 
delayed protection.  
It is known that activation of signaling pathways is involved in the development of the early 
protection [8]. For example, adenosine, bradykinin, and opioids that are generated and released 
by brief preconditioning ischemic periods bind to GPCRs and lead to activation of the PI3K 
pathway and of its downstream targets, such as Akt or ERK [8]. Akt (also known as PKB) has a 
central role in the regulation of other proteins by phosphorylation [24]. Akt phosphorylates and 
thereby activates eNOS which thus produces nitric oxide, which is one of the key messenger 
molecules both in the early and the late survival pathways [62]. Furthermore, Akt can also inhibit 
target proteins through phosphorylation such as GSK3β and the proapoptotic BAD or casp3 and 9 
which, result in the inhibition of apoptotic processes during ischemia and reperfusion [24]. It has 
been suggested that PKCε is also activated by the PI3kinase, possibly through the Akt-eNOS-
sGC mediated pathways [17]. ERK is also activated by PKCε [25] in response to a 
preconditioning stimulus and phosphorylates the proapoptotic factor BAD.  
In our present studies, several members of the signaling pathways were examined to determine 
their alterations following cardiac pacing (time-dependent study) and also during ischemia and 
reperfusion in the time of the delayed cardioprotection. As mentioned above, several members of 
signaling pathways have been proposed to be activated by a PC stimulus, but little is known how 
the expression of these genes is changed before and during the late phase of the protection. There 
is a lack of information about the sequence of gene expression changes during that time interval, 
which elapses between the PC stimulus and the appearance of the delayed protection.  
We have found that genes encoding PKCε, ERK1 and different isoforms of sGC were early up-
regulated after cardiac pacing (Figure 3). For example, the gene encoding PKCε was markedly 
expressed at all the observed time points and remained up-regulated during ischemia. The 
transcription of this gene was also increased (not significant) after the myocardial ischemia but it 
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was not significantly altered at the time of the delayed phase of protection induced by pacing. 
Even so, the marked up-regulation of PKCε immediately and 24h after the pacing stimulus might 
indicate a role in both phases of the antiarrhythmic protection. There is pharmacological evidence 
that the activation of and the following translocation of PKCε is necessary for the development of 
late protection [63, 64].  
The expression of genes encoding sGCα1 and sGCβ1 was not significantly altered either by 
ischemia in dogs subjected to a 25 min ischemia/reperfusion insult (PO vs. IC). However, these 
genes were changed following cardiac pacing in a biphasic pattern. They were immediately up-
regulated after the pacing stimulus (P-0h vs. SP) after which they were either normalized or 
down-regulated. However, these genes were up-regulated again 12 or 24h after pacing (Figure 3). 
The importance of sGC-mediated signaling pathway in the early protection was suggested in our 
previous study in which the administration of methylene blue completely abolished the early 
antiarrhythmic effect of ischemic preconditioning [10]. More recent studies, using ODQ a 
selective inhibitor of sGC, have confirmed the role of NO-sGC pathway in the early [65] and also 
in the late [66] phase of the protection. The present results which clearly show a biphasic 
transcriptional activation of sGCα1, sCGα2 and sGCβ1 following cardiac pacing, provide a 
further support for the role of this pathway in both phases of the protection. 
Another gene GSK3β which was markedly altered after cardiac pacing is one of the key members 
of the preconditioning-induced survival pathway [8]. The enzymatic activity of this kinase is 
inhibited by phosphorylation and by interaction with other proteins. Under normal conditions, 
GSK3β is active and usually inactivates its primed substrates. As a key kinase it integrates 
multiple signaling pathways, and regulates many cellular processes, such as it inhibits 
transcription factors and induces apoptosis [67]. It has been found that preconditioning by 
inhibiting GSK3β through phosphorylation, results in cardioprotection [68]. Signaling through 
Akt, PKC, PKA and ERK phosphorylates and therefore inhibits GSK3β, which in turn reduces 
the phosphorylation and activation of different proteins, such as the pro-apoptotic BAX [69], or 
inhibits the opening and formation of the mPTPs [21]. In our study, the expression of GSK3β was 
markedly down-regulated at almost each time point in the paced dogs. Furthermore, pacing 
reduced GSK3β expression during ischemia compared with the unpaced controls in which the 
transcription of this gene was considerably increased (Figure 3). This and the previous results 
indicate that cardiac pacing keeps the expression of the cardioprotective kinases, such as PKCε, 
PKCa, ERK1, sGCα1/β1, up-regulated over a longer period of time whereas it down-regulates 
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the transcription of GSK3β. These results suggest that pacing facilitates the survival pathways 
during the both phases of the protection and suppresses the expression of genes which are 
involved in the harmful consequences of ischemia/reperfusion.  
It is well established that NO, released during a preconditioning stimulus, plays a trigger and 
mediator role in both the early and delayed phase of the protection [9, 30]. We have now 
provided further evidence for this by demonstrating a marked increase in the transcription of both 
eNOS and iNOS 12h after cardiac pacing. Furthermore, this was the only time point when the 
expression of these genes was significantly up-regulated (Figure 4). This finding might have a 
particular importance, since previous studies in conscious rabbits have reported that the activity 
of eNOS and nNOS was increased only immediately after preconditioning, but it was not affected 
24h later [45], whereas the transcription of iNOS was up-regulated only at the time of the late 
phase of the protection [32].  
There is no doubt that iNOS expression and the resultant increase in NO generation is essential 
for the development of the delayed antiarrhythmic protection. We have pharmacological evidence 
for this using various, more or less selective inhibitors of iNOS [6, 29, 31, 44], which are all 
markedly attenuated or even abolished the delayed protection against arrhythmias resulted from 
cardiac pacing [6, 29, 31] or heavy physical exercise [44, 70]. Since, these inhibitors are not 
entirely selective for iNOS the role of eNOS-derived NO formation in the delayed phase of the 
protection can not be ruled out. To support this hypothesis we have performed additional 
experiments to measure eNOS protein content and activation (Figure 5). The results show that 
eNOS protein content was significantly increased in the paced dogs, whereas the activity of this 
enzyme was increased twice; i.e. immediately and 24h after pacing (Figure 5b). Thus we suggest, 
like the others [32, 45] that the release of NO immediately after the preconditioning stimulus 
most likely results from the increased activation of eNOS. This NO by stimulating the transcript 
of iNOS and eNOS, that occurs in dogs 12h after pacing, results in further NO generation and 
availability at the time of the delayed protection. However, in contrast with others [32, 45], we 
propose that an increase in eNOS protein expression and activity, besides the increased iNOS 
activation, may also play a role in NO production which mediates the late phase of the protection.  
There are studies that confirm that anti-apoptotic processes, such as deletion of apoptotic proteins 
[71] or increased expression of anti-apoptotic factors [72, 73] reduce the ischemia-reperfusion 
mediated cell death. Other results also demonstrate that PC attenuates apoptotic cell death by 
decreasing the transcription of the pro-apoptotic BAX [74] and by increasing the expression of 
36 
the anti-apoptotic Bcl-2 [75]. The present results demonstrate that the anti-apoptotic Bcl-2 was 
mostly up-regulated (immediately, 12 and 24 after cardiac pacing), whereas genes encoding the 
pro-apoptotic BAX and members of the apoptotic caspase cascade were down-regulated at 
various time points. In the ischemic controls the pro-apoptotic genes were enhanced while in the 
paced dogs, subjected to coronary artery occlusion and reperfusion 24h later, the pro-apoptotic 
genes were markedly down-regulated. These results demonstrate that cardiac pacing protects the 
heart against apoptotic cell death. 
Rapid cardiac pacing also modified the expression of the gene encoding the main gap junction 
forming protein Cx43. It was down-regulated 6 h after rapid cardiac pacing and was up-regulated 
again at 12 h. In our previous study we have found that pacing influenced the protein expression 
and the subcellular location of Cx43 [41]. According to these results, twelve hours after the 
pacing stimulus the protein content of Cx43 was decreased and this was preceded by a down-
regulation of mRNA at 6 h. Also, the signals obtained from the Cx43-labeled 
immunofluorescence images showed that the ischemia-induced structural impairment of the 
intercalated discs was preserved after the pacing stimulus. Preconditioning also preserved gap 
junction permeability and Cx43 phosphorylation compared to the ischemic controls.  
In summary, these results provide evidence for the first time that cardiac pacing induces time-
course dependent gene expression changes, which contribute to the appearance of the early and 
the late phase of the protection. We have found genes which were immediately altered after rapid 
cardiac pacing. These encode proteins that are already known to have a role in the early phase of 
protection. Some of these genes preserved their altered transcription over a 24h time interval, 
whereas others showed a biphasic (early and late) activation pattern, indicating a role of these 
genes in the development of delayed phase of the antiarrhythmic protection. There were a few 
genes which were altered at later time points. For example, iNOS or eNOS were activated 12 h 
after the PC stimulus and these changes resulted in enhanced protein production at 24h, when the 
late phase usually appears. We are aware that changes in gene expression does not provide 
information about the protein content, but these present results provide evidence for a time-
dependent change in gene expression which occur between the PC stimulus and the appearance 
of the delayed protection.  
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